

Curriculum Vitae - Hilde Furberg

Born: August 1, 1958, Oslo, Norway

Civil status: Engaged
Two children: Jacob (-93) and Julie (-92)

Education: Cand. Scient University of Oslo, 1982
Marketing at Norway Business School, 1989
"Managing Corporate Resources", IMD 1994

Language: Norwegian, Danish, Swedish & English fluent,
Some German



Professional Career:

From 2002 **Genzyme**

2010 Senior Vice President RD (Rare Diseases) EMEA

Key responsibilities:

Deliver EMEA P&L

Sett strategic direction and targets for country organizations

Liaise between Region and Global BU

Competitive strategy, Planning and launching of new products in Region, including early access program

Dual reporting lines to Global President RD in US and President EMEA

2006 Vice President & General Manager

Nordic Benelux

Maximize business opportunity for the cluster; full P&L responsibility.

Deliver short and long term target, build organization with competencies needed to deliver business expectation, including launch of new products, on average 1 product pr year, orphan as well as "normal" drugs.

Therapeutic Area: Rare Genetic Diseases, Nephrology, Endocrinology, Oncology and Biosurgery

Scope: commercial, medical, regulatory, finance, distribution, HR.

2002 Nordic General Manager

Start and build the Nordic business. Everything from establishing legal entity, opening offices, building the organization, launching products++ all you do when you start a new business in a local market.

1998 - 02

Pharmalink A/S

Managing Director and part-owner, Denmark

1996 – 98

Baxter

Managing Director Sweden, Coordinating CMD Nordic & Baltic, Business Unit Director Hospital Division Nordic & Baltic, Sweden

1989 – 96

Business Unit Director, Renal Division Baxter, Nordic/Baltic, Denmark.

1988 – 89

Business Unit Manager Renal and Hospital Division, Norway

1985 – 88

Product Manager Diagnostica and Hospital, Norway

1983 – 85

Sales representative, South Norway

Hilde Furberg

Overgaden neden Vandet 33,3, 1414 København K
+45-32 95 30 91 (private) +45-40 91 15 91 (mobile)

Professional Board Membership:

Algeta ASA, Board Member since April 2013 (Oslo stock exchange)

Clavis, Board Member May 2012-April 2013 (Oslo stock exchange)

Pronova, Board Member May 2011- Feb 2013 (Oslo stock exchange)

Copenhagen Capacity, Board Member since November 2007 (Non profitable. Attracting investment to broader CPH region, board members 50% politicians, 50% enterprises)

Probi AB, Board Member 2005- 2011 (Stockholm stock exchange)

Publication:

Determination of trace element associated with colloidal material in seawater using INAA and RNAA. UiO, 1984

Central preparation of antibiotic admixtures including freezing and Thawing by Microwave radiation. Norwegian Pharmacy Paper, 1985.

Measurement of the particle counts in different antibiotic solutions prior to and after freezing and thawing. Nor.Pharm.Acta, 1986.

Effect of pretreatment with 0.9% sodium chloride or insulin solution on the delivery of insulin from an infusion system. Am J Hosp Pharm, 1986.

Hilde Furberg

Overgaden neden Vandet 33,3, 1414 København K
+45-32 95 30 91 (private) +45-40 91 15 91 (mobile)

CURRICULUM VITAE, Stener Kvinnsland

Vitae:

Age and social status: 66 years, married, 4 children, 12 grandchildren

Education:

June, 1967: High school degree

June, 1973: Medical degree (MD), University of Bergen.

June 1973: Associate professor, Dept. of Anatomy
University of Bergen

March, 1980: PhD. thesis: The role of cyclic AMP in the
mechanism of action of estradiol. University of
Bergen.

January, 1986: Specialist in medical oncology and radiotherapy

Positions and appointments:

Sept., 1984: Consultant in Oncology, Dept. of Oncology,
University of Bergen.

January, 1987: Head of department, Dept. of Oncology, and
Professor in medicine (oncology), University of
Trondheim.

June, 1987 – 1994: Member of the board, Norwegian Cancer Registry

December, 1990 – 94: Chairman, The Norwegian Breast Cancer Group

September, 1991: Consultant in Oncology and Radiotherapy,
The Norwegian Radium Hospital, Oslo, Professor
in medicine (oncology), University of Trondheim
(until 28.02.92)

Febr. 1992 – Dec. 94: Head of Department, Department of Oncology
(200 beds), The Norwegian Radiumhospital.

May 1992 – Sept.00 Chairman of the board, The Norwegian Cancer
Society

October, 1992 – 94:	Chairman, the Scandinavian Breast Group
May, 1994 – Des. 94:	Professor in medicine (oncology), University of Oslo.
Oct, 1994 – June 02:	Member of Council, International Union against Cancer (UICC).
Januar, 1995 – Sept. 96:	Director clinical R & D, Oncology Pharmacia & Upjohn, Milan – Italy. Responsability: Worldwide clinical development of cancer drugs.
Sept. 1996 – Sept.02	Professor in medicine (Oncology), University of Oslo. Head of dept., Dept. of Oncology, The Norwegian Radiumhospital.
Sept. 1998 - 2000	Chairman-elect, Committee of International Collaborative Activity (CICA) in International Union against Cancer (from Aug. 1998)
1999 – 2001	Board Member, Photocure ASA (listed Oslo Stock Exchange)
Sept. 2000 – Febr. 02	Senior Adviser, Norwegian Cancer Society
Sept. 2000 – June 02	Secretary General, International Union against Cancer (UICC – Geneva)
Febr. 02 – March 03	Head of Dept., Dept. of Oncology and Medical physics, Haukeland Universityhospital
Febr. 02 – dec. 06	Professor of Medicine (Oncology), Medical faculty, University of Bergen
April 03 – dec. 06	Vicepresident Bergen Hospital Trust (Helse Bergen)
Jan. 07 – dd	CEO Bergen Hospital Trust (Helse Bergen)
Oct. 2011- dd	Chair of Board, Oslo University Hospital

Scientific work:

Publications: 130 papers: Cell biology; growth regulation; hormone mechanism of action; carcinogenesis; epidemiology; quality of life issues; endocrine therapy (mechanism of action), endocrine therapy (pharmacological aspects), endocrine therapy (clinical trials);

other clinical trials, organizational aspects of cancer care.
Special interest: All aspects of breast cancer.

Bergen, april 2015

Stener Kvinnsland MD, PhD